2024
REDOMA: Bayesian random‐effects dose‐optimization meta‐analysis using spike‐and‐slab priors
Yang C, Kwiatkowski E, Lee J, Lin R. REDOMA: Bayesian random‐effects dose‐optimization meta‐analysis using spike‐and‐slab priors. Statistics In Medicine 2024, 43: 3484-3502. PMID: 38857904, PMCID: PMC11789924, DOI: 10.1002/sim.10107.Peer-Reviewed Original ResearchConceptsOptimal biological doseDose-efficacy curveDose efficacyPhase I/II trialMeta-analysisOncology trialsSpike-and-slabMultiple phase IDose-toxicity relationshipPrecision cancer treatmentEarly-phase oncology trialsOncological therapyBiological doseEfficacy dataSpike-and-slab priorsTreatment efficacyCancer treatmentExtensive simulation studyTrialsEfficacyBayesian model selection frameworkTreatmentPhase IDoseGamma processThe Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature
Belzer A, Pach J, Valido K, Leventhal J. The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature. American Journal Of Clinical Dermatology 2024, 25: 435-445. PMID: 38366030, DOI: 10.1007/s40257-024-00847-2.Peer-Reviewed Original ResearchDermatologic adverse eventsAdverse eventsQuality of lifeManagement of dermatologic adverse eventsDiscontinuation of treatmentDermatology Life Quality IndexQuality of life of oncological patientsLife Quality IndexRadiation therapyCytotoxic chemotherapyDose reductionOral mucosaTargeted therapyOncological therapyProphylactic treatmentDrug classesEarly managementOncology patientsPatientsQuality-of-life concernsLife-prolonging treatmentTherapyPatient well-beingDeclining quality of lifeImpact patients
2023
Characterizing skin and soft tissue infections in patients with cancer on systemic oncologic therapy: A single institution retrospective analysis from the outpatient and inpatient oncodermatology service
Pach J, Nelson C, Leventhal J. Characterizing skin and soft tissue infections in patients with cancer on systemic oncologic therapy: A single institution retrospective analysis from the outpatient and inpatient oncodermatology service. JAAD International 2023, 15: 21-23. PMID: 38371669, PMCID: PMC10869938, DOI: 10.1016/j.jdin.2023.11.011.Peer-Reviewed Original Research
2016
National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study
Mahal B, Chen Y, Efstathiou J, Muralidhar V, Hoffman K, Yu J, Feng F, Beard C, Martin N, Orio P, Nguyen P. National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. Cancer 2016, 122: 1505-1512. PMID: 26970022, DOI: 10.1002/cncr.29960.Peer-Reviewed Original ResearchConceptsProton therapy useProstate cancerProton therapyTherapy useIncreasing use of proton therapyMultivariable adjustmentUse of proton therapyNational Cancer Data BaseLong-term follow-upExternal beam radiotherapyMultivariate logistic regression analysisHigh-grade diseaseNonmetastatic prostate cancerFactors associated with receiptNationwide cancer registryLogistic regression analysisBeam radiotherapyDefinitive therapyOncological therapyNonacademic centersTreated patientsClinical factorsFollow-upProstateCancer Registry
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply